Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aligos Therapeutics, Inc. (ALGS : NSDQ)

• Company Description    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif. Number of Employees: 70

• Price / Volume Information    Yesterday's Closing Price: $10.20 Daily Weekly Monthly 20 Day Moving Average: 70,889 shares Shares Outstanding: 6.15 (millions) Market Capitalization: $62.74 (millions) Beta: 2.79 52 Week High: $46.80 52 Week Low: $3.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 34.48% 32.11% 12 Week 21.86% 10.70% Year To Date -74.40% -75.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE CORPORATE DR. 2ND FLOOR - SOUTH SAN FRANCISCO,CA 94080 USA ph: 800-466-6059 fax: - jtarazi@aligos.com http://www.aligos.com

• General Corporate Information    Officers Lawrence M. Blatt - Chairman; President; and Chief Executive Officer Lesley Ann Calhoun - Executive Vice President; Chief Operating Officer K. Peter Hirth - Director James Scopa - Director Margarita Chavez - Director Peer Information Aligos Therapeutics, Inc. (CORR.) Aligos Therapeutics, Inc. (RSPI) Aligos Therapeutics, Inc. (CGXP) Aligos Therapeutics, Inc. (BGEN) Aligos Therapeutics, Inc. (GTBP) Aligos Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 01626L204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 6.15 Most Recent Split Date: 8.00 (0.04:1) Beta: 2.79 Market Capitalization: $62.74 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-8.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.62 Price/Cash Flow: - Price / Sales: 19.77 EPS Growth vs. Year Ago Period: -304.00% vs. Previous Quarter: 27.49% Sales Growth vs. Year Ago Period: -9.05% vs. Previous Quarter: 210.29% ROE 06/30/25 - -22.41 03/31/25 - 14.67 12/31/24 - -190.19 ROA 06/30/25 - -12.09 03/31/25 - 7.19 12/31/24 - -71.29 Current Ratio 06/30/25 - 6.31 03/31/25 - 7.56 12/31/24 - 2.86 Quick Ratio 06/30/25 - 6.31 03/31/25 - 7.56 12/31/24 - 2.86 Operating Margin 06/30/25 - -422.56 03/31/25 - 229.73 12/31/24 - -1,785.53 Net Margin 06/30/25 - -2,337.24 03/31/25 - -1,628.75 12/31/24 - -3,326.01 Pre-Tax Margin 06/30/25 - -2,326.34 03/31/25 - -1,618.04 12/31/24 - -3,317.62 Book Value 06/30/25 - 16.56 03/31/25 - 19.05 12/31/24 - -7.50 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - 0.12 03/31/25 - 0.10 12/31/24 - -

Powered by Zacks Investment Research ©